<DOC>
	<DOCNO>NCT01515592</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial ass safety tolerability 20 µg/kg 25 µg/kg liraglutide healthy Japanese male subject .</brief_summary>
	<brief_title>Safety Tolerability Liraglutide Healthy Japanese Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Healthy Japanese subject BMI ( Body Mass Index ) 18.027.0 kg/m^2 inclusive Any clinical laboratory value deviate reference range laboratory ( except case within physiological change ) abnormal ECG ( electrocardiogram ) finding screen Presence diabetes , cancer clinically significant cardiac , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , dermatological , venereal , haematological , neurological , psychiatric disease disorder Hepatitis B surface antigen , Hepatitis C antibody HIV ( human immunodeficiency virus ) antibodies positive History diabetes , cancer clinically significant cardiac , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , dermatological , venereal , haematological , neurological , psychiatric disease disorder History significant allergy hypersensitivity Known suspect allergy trial product related product History drug alcohol abuse The subject smoke 15 cigarette , equivalent , per day unwilling refrain smoke whenever require trial procedure</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>